Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(29 sites) Australia
Royal Brisbane and Women'S Hospital, Herston, Queensland Royal Adelaide Hospital, Adelaide, South Australia Peter Maccallum Cancer Centre, Melbourne, Victoria The Alfred Hospital, Melbourne, Victoria Canada
Princess Margaret Cancer Center, Toronto, Ontario Hopital Maisonneuve-Rosemont, Montreal, Qc, Montreal, Quebec Denmark
Odense University Hospital, Odense C Sjaellands Universitetshospital, Roskilde France
Institut Bergonie, Bordeaux Hospital Saint Louis, Paris Institut Gustave Roussy, Villejuif Germany
University Medical Center Rwth Aachen, Aachen Universitatsklinikum Halle (Saale), Halle Universitätsklinikum Ulm, Ulm Italy
Aou Policlinico S. Orsola-Malpighi, Bologna Azienda Ospedaliero-Universitaria Careggi (Aouc), Florence Fondazione Irccs Ca Granda Ospedale Maggiore, Milan Japan
National Cancer Center Hospital East, Chiba-ken Kagoshima University Hospital, Kagoshima Osaka Metropolitan University Hospital, Osaka Nippon Medical School Hospital, Tokyo Mie University Hospital, Tsu Spain
Hospital Universitario 12 de Octubre, Madrid Hospital Universitari I Politecnic La Fe, Valencia United Kingdom
Guys and St Thomas Nhs Foundation Trust, London The Christie Nhs Foundation Trust Uk, Manchester University of Oxford, Oxford